- Home
- NL vs SLS Comparison
NL vs SLS Comparison
Compare NL & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NL
- SLS
- Stock Information
- Founded
- NL 1891
- SLS 2012
- Country
- NL United States
- SLS United States
- Employees
- NL N/A
- SLS N/A
- Industry
- NL Major Chemicals
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NL Industrials
- SLS Health Care
- Exchange
- NL Nasdaq
- SLS Nasdaq
- Market Cap
- NL 283.9M
- SLS 238.7M
- IPO Year
- NL N/A
- SLS N/A
- Fundamental
- Price
- NL $5.80
- SLS $1.59
- Analyst Decision
- NL
- SLS Strong Buy
- Analyst Count
- NL 0
- SLS 1
- Target Price
- NL N/A
- SLS $7.00
- AVG Volume (30 Days)
- NL 37.5K
- SLS 5.4M
- Earning Date
- NL 11-06-2025
- SLS 11-07-2025
- Dividend Yield
- NL 9.66%
- SLS N/A
- EPS Growth
- NL N/A
- SLS N/A
- EPS
- NL 0.20
- SLS N/A
- Revenue
- NL $159,004,000.00
- SLS N/A
- Revenue This Year
- NL $15.75
- SLS N/A
- Revenue Next Year
- NL $2.44
- SLS N/A
- P/E Ratio
- NL $29.73
- SLS N/A
- Revenue Growth
- NL 5.52
- SLS N/A
- 52 Week Low
- NL $5.29
- SLS $0.77
- 52 Week High
- NL $9.42
- SLS $2.48
- Technical
- Relative Strength Index (RSI)
- NL 45.58
- SLS 35.18
- Support Level
- NL $5.67
- SLS $1.85
- Resistance Level
- NL $6.00
- SLS $2.06
- Average True Range (ATR)
- NL 0.27
- SLS 0.14
- MACD
- NL 0.01
- SLS -0.05
- Stochastic Oscillator
- NL 23.14
- SLS 6.03
About NL NL Industries Inc.
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.